AstraZeneca PLCLong
BULLISH ON AZN
AstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not yet in overbought territory, suggesting there’s still room for growth
Trendline support: The stock is currently around the trendline support
STOCK ANALYSIS
Support Levels: AZN’s stock is trading close to its key support levels, around $66.26, and has shown resilience above the $60 mark, which historically has been a strong support zone. The stock is likely to maintain upward pressure if it holds above this level
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.